Compare Revvity Inc (RVTY) vs S&P500 ETF (SPY) Price & Performance

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

SPY, the SPDR S&P 500 ETF Trust, trades at $772.90 with minimal daily movement (-0.02%). Technical indicators show a bullish trend with moving averages supporting upside momentum, though oscillators signal potential overbought conditions. The ETF maintains its position as the world's largest fund with approximately $676 billion in assets. Recent news highlights the S&P 500 reaching record highs while facing valuation concerns with the Shiller P/E ratio at 42, the highest since the dot-com era.

The ETF's outlook remains positive with institutional targets pointing toward 8,000 levels, though elevated valuations and weak market breadth present near-term risks. Dividend income continues to attract investors with reliable distributions, but fee comparisons with competing funds highlight cost considerations for long-term holders.